Peter Attia· MD
what the phase two studies obviously the toxicity passed in F in phase one yes yeah I I'm not concerned there doesn't seem to be any adverse effect of these drugs or they wouldn't got through phase two
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
what the phase two studies obviously the toxicity passed in F in phase one yes yeah I I'm not concerned there doesn't seem to be any adverse effect of these drugs or they wouldn't got through phase two
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and they do have some concerns about these drugs these myat inhibites that actually may have some negative effects on the heart and my suggestion is actually you may find a big Improvement in myocardial function uh from uh these uh how where are myostatin Inhibitors in their development right now phase two